## **Appendix 3B**

# New Issue Announcement, Application for Quotation of Additional Securities and Agreement

Information or documents not available now must be given to ASX as soon as available.

Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

	•		
OPTIS	SCAN IMAGING LIMITED (ASX: OIL)		
ABN			
81 077	7 771 987		
We (t	he entity) give ASX the following information.		
Part	Part 1 - All issues		
You mu	You must complete the relevant sections (attach sheets if there is not enough space).		
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Performance Rights     Unlisted Options	
		3. Unlisted Options	

- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- 1. 2,600,000

4. Unlisted Options5. Unlisted Options

- 2. 6,400,000
- 3. 6,400,000
- 4. 6,400,000
- 5. 6,400,000

Name of Entity

- Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)
- 1. Performance Rights
- Unlisted Options, exercisable at \$0.05, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.08 after 31 May 2019 and expiring 31 May 2022
- 3. Unlisted Options, exercisable at \$0.05, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.08 after 30 November 2019 and expiring 30 November 2022
- 4. Unlisted Options, exercisable at \$0.065, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.08 after 31 May 2020 and expiring 31 May 2023
- Unlisted Options, exercisable at \$0.08, upon the Company's share price average being equal to or greater than a 14 day VWAP of \$0.10 after 30 November 2020 and expiring 30 November 2023
- 4 Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

- 1. No upon exercise of performance rights, securities will rank equally with existing fully paid ordinary shares.
- 2. No upon exercise of options, securities will rank equally with existing fully paid ordinary shares.
- 3. No upon exercise of options, securities will rank equally with existing fully paid ordinary shares.
- 4. No upon exercise of options, securities will rank equally with existing fully paid ordinary shares
- 5. No upon exercise of options, securities will rank equally with existing fully paid ordinary shares.

5 Issue price or consideration

- 1. Nil
- 2. Nil
- 3. Nil
- 4. Nil
- 5. Nil

6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	<ol> <li>Issued pursuant to Resolutions 3, 4 and 5 of the Company's Notice of Annual General Meeting approved by Shareholders on 30 November 2018 and in accordance with the Company Incentive Options &amp; Performance Rights Plan.</li> <li>2 – 5. Issued pursuant to Resolutions 6 and 7 of the Company's Notice of Annual General Meeting approved by Shareholders on 30 November 2018 and in accordance with the Company Incentive Options &amp; Performance Rights Plan.</li> </ol>
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h <i>in relation to the</i> *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	30 November 2018
6c	Number of *securities issued without security holder approval under rule 7.1	Nil
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil
6f	Number of <sup>+</sup> securities issued under an exception in rule 7.2	<ol> <li>2,600,000 Performance Rights</li> <li>6,400,000 Unlisted Options</li> <li>6,400,000 Unlisted Options</li> <li>6,400,000 Unlisted Options</li> <li>6,400,000 Unlisted Options</li> </ol>
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under rule 7.1A for non- cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	See Annexure 1

<sup>+</sup> See chapter 19 for defined terms. 04/03/2013

7	<sup>†</sup> Issue dates		20 De	cember 2018	
	Note: The issue date may be prescribed by ASX (refer to issue date in rule 19.12). For example, the issue date entitlement issue must comply with the applicable timeta 7A.	for a pro rata			
	Cross reference: item 33 of Appendix 3B.	L			_
		Number		<sup>†</sup> Class	
8	Number and *class of all *securities quoted on ASX ( <i>including</i> the *securities in section 2 if applicable)	432,678,800	)	Fully Paid Ordinary Shares	
		Number		+Class	_
9	Number and *class of all *securities not quoted on ASX ( <i>including</i> the *securities in section 2 if applicable)	2,600,000		Performance Rights	
		6,400,000		Unlisted Options, exercisable at \$0.05, expiring 31 May 2022	
		6,400,000		Unlisted Options, exercisable at \$0.05, expiring 30 November 2022	
		6,400,000		Unlisted Options, exercisable at \$0.065, expiring 31 May 2023	
		6,400,000		Unlisted Options, exercisable at \$0.08, expiring 30 November 2023	
10	Dividend policy (in the case of a trust, policy) on the increased capital (interests		N/A		
Part :	2 - Pro rata issue				
11	Is security holder approval required?		N/A		_
12	Is the issue renounceable or non-renoun	ceable?	N/A		_
13	Ratio in which the *securities will be offe	red	N/A		_
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer re	lates	N/A		_
15	*Record date to determine entitlements		N/A		_
16	Will holdings on different registers (or significant temperature) be aggregated for calculating entitlement		N/A		_

fractions

17

Policy for deciding entitlements in relation to N/A

18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
		C
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements in full through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	†Issue date	N/A
		1
art 3	3 - Quotation of securities	

You need only complete this section if you are applying for quotation of securities

34 Type of \*securities (tick one)

\*Securities described in Part 1 (a)

	st But excluding the options set out at item (b) $lpha$	of item 1.	
(b)	All other *securities		
	Example: restricted securities at the end of the escrowed period, pa securities when restriction ends, securities issued on expiry or conve		fully paid, employee incentive share
Entitie	s that have ticked box 34(a)		
Additio	nal securities forming a new class of securities		
Tick to	indicate you are providing the information or documents		
35	If the *securities are *equity securities, the nate *securities, and the number and percentage of a		
36	If the *securities are *equity securities, a dist setting out the number of holders in the catego 1 - 1,000		he additional *securities
	1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over		
37	A copy of any trust deed for the additional *sec	urities	
Entitie	s that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought	N/A	
39	*Class of *securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next		
	<ul> <li>dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>		
41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Ni. wala au	+Class
42	Number and teless of all teasurities avoided on ASV	Number N/A	*Class N/A
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	IN/A	IV/A

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
    - Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
  - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
  - If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Justin Mouchacca Company Secretary Date: 20 December 2018

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which	h the placement capacity is calculated	
<b>Insert</b> number of fully paid <sup>+</sup> ordinary securities on issue 12 months before the <sup>+</sup> issue date or date of agreement to issue	425,978,800	
<ul> <li>Add the following:         <ul> <li>Number of fully paid †ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid †ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid †ordinary securities that became fully paid in that 12 month period</li> </ul> </li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> <li>Subtract the number of fully paid †ordinary securities cancelled during that 12 month period</li> </ul>	5,200,000 shares on 29 January 2018 760,000 shares on 7 June 2018 740,000 shares on 27 June 2018	
"A"	432,678,800	

Step 2: Calculate 15% of "A"	
"B"	0.15 [Note: this value cannot be changed]
Multiply "A" by 0.15	64,901,820

Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
<b>Insert</b> number of *equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	-	
Under an exception in rule 7.2		
Under rule 7.1A		
With security holder approval under rule 7.1 or rule     7.4		
Note:  This applies to equity securities, unless specifically excluded – not just ordinary securities  Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed  It may be useful to set out issues of securities on different dates as separate line items		
"C"	-	

Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15  Note: number must be same as shown in Step 2	64,901,820	
Subtract "C"  Note: number must be same as shown in Step 3	-	
<b>Total</b> ["A" x 0.15] – "C"	64,901,820 [Note: this is the remaining placement capacity under rule 7.1]	

### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<b>"A"</b> 432,678,800		
Note: number must be same as shown in Step 1 of Part 1		

Step 2: Calculate 10% of "A"	
"D"	0.10  Note: this value cannot be changed
Multiply "A" by 0.10	43,267,880

Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	-	
<ul> <li>Notes:         <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> </ul> </li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	-	

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
" <b>A</b> " x 0.10	43,267,880
Note: number must be same as shown in Step 2	
Subtract "E"	-
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	43,267,880
	Note: This is the remaining placement capacity under rule 7.1A